Your browser doesn't support javascript.
loading
A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening.
Xiong, Bin; Gui, Chun-Shan; Xu, Xiao-Ying; Luo, Cheng; Chen, Jing; Luo, Hai-Bin; Chen, Li-Li; Li, Guo-Wei; Sun, Tao; Yu, Chang-Ying; Yue, Li-Duo; Duan, Wen-Hu; Shen, Jing-Kang; Qin, Lei; Shi, Tie-Liu; Li, Yi-Xue; Chen, Kai-Xian; Luo, Xiao-Min; Shen, Xu; Shen, Jian-Hua; Jiang, Hua-Liang.
Afiliación
  • Xiong B; Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 201203, China.
Acta Pharmacol Sin ; 24(6): 497-504, 2003 Jun.
Article en En | MEDLINE | ID: mdl-12791174
AIM: To constructed a three-dimensional (3D) model for the 3C like (3CL) proteinase of SARS coronavirus (SARS-CoV), and to design inhibitors of the 3CL proteinase based on the 3D model. METHODS: Bioinformatics analyses were performed to search the homologous proteins of the SARS-CoV 3CL proteinase from the GenBank and PDB database. A 3D model of the proteinase was constructed by using homology modeling technique. Targeting to the 3D model and its X-ray crystal structure of the main proteinase (Mpro) of transmissible gastroenteritis virus (TGEV), virtual screening was performed employing molecular docking method to identify possible 3CL proteinase inhibitors from small molecular databases. RESULTS: Sequence alignment indicated that the SARS-CoV 3CL proteinase was extremely homologous to TGEV Mpro, especially the substrate-binding pocket (active site). Accordingly, a 3D model for the SARS-CoV 3CL proteinase was constructed based on the crystal structure of TGEV Mpro. The 3D model adopts a similar fold of the TGEV Mpro, its structure and binding pocket feature are almost as same as that of TGEV Mpro. The tested virtual screening indicated that 73 available proteinase inhibitors in the MDDR database might dock into both the binding pockets of the TGEV Mpro and the SARS-CoV 3CL proteinase. CONCLUSIONS: Either the 3D model of the SARS-CoV 3CL proteinase or the X-ray crystal structure of the TGEV Mpro may be used as a starting point for design anti-SARS drugs. Screening the known proteinase inhibitors may be an appreciated shortcut to discover anti-SARS drugs.
Asunto(s)
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cisteína Endopeptidasas / Inhibidores de Cisteína Proteinasa / Síndrome Respiratorio Agudo Grave / Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Acta Pharmacol Sin Asunto de la revista: FARMACOLOGIA Año: 2003 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Buscar en Google
Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cisteína Endopeptidasas / Inhibidores de Cisteína Proteinasa / Síndrome Respiratorio Agudo Grave / Coronavirus Relacionado al Síndrome Respiratorio Agudo Severo Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Acta Pharmacol Sin Asunto de la revista: FARMACOLOGIA Año: 2003 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos